U.S. Need For Biotech Generic Drugs Seen As Boon For China
This article was originally published in PharmAsia News
Executive Summary
Drug policy pressures on the United States could have an ancillary effect of making more Chinese drug firms bigger players in the world market, one expert believes. Dr. Jim Wei, a former senior reviewer for the U.S. FDA and now director of clinical pharmacology at the contract research organization Medpace, says the pressure on the United States to lower drug prices encourages foreign drug makers to enter the market for generic drugs. He said that situation is leading to an increase in the need for generic protein drugs, an area of biotech drugs where the legality of copying is hazy in the United States. As the demand rises, "Chinese manufacturers have the ability to produce such products," Wei says. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.